Treatment with BIX-01294 reduces cell proliferation, and this is observed to an even greater degree upon combination with DN-TBX2, a mutant TBX2 protein containing an absent T-box domain, suggesting that G9a and TBX2 may have a synergistic role in driving breast cancer cell proliferation [142]. Here, EHMT2 is linked to breast cancer.